Quick Search 
Drug News & Perspectives
Register or sign in

  
 
  
Drug News Perspect 2002, 15(9): 558
ISSN 0214-0934
Copyright 2002 Clarivate Analytics
CCC: 0214-0934
 

The current challenge of pharmacogenetics is to identify the genetic factors underlying differential drug response.

Pharmacogenetic Development of Personalized Medicine: Multiple Sclerosis Treatment as a Model

by Iris Kirstein-Grossman, Jacques S. Beckmann, Doron Lancet and Ariel Miller


Summary

The goal of pharmacogenetics is to identify "genetic fingerprints" that may predict a patient's response to pharmaceutical treatment. The use of pharmacogenetics replaces the trial-and-error strategy, which governs much of our clinical decision-making regarding treatment allocation in current medical practice, with individually tailored therapy. We review a pharmacogenetic research model, which implements high-throughput single nucleotide polymorphism technology to establish the correlation between drug-responsiveness and genetic polymorphisms of Copaxone®-treated multiple sclerosis patients. Implementation of similar pharmacogenetic approaches may promote the development of personalized medicine in multiple sclerosis as well as in other diseases. © 2002 Prous Science. All rights reserved.



Full Text: HTMLPDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy